Mesenchymal stem cells modified by FGF21 and GLP1 ameliorate lipid metabolism while reducing blood glucose in type 2 diabetic mice
Open Access
- 15 February 2021
- journal article
- research article
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 12 (1) , 1-15
Abstract
Objective: The purpose of this study was to investigate the therapeutic effects of genetically modified mesenchymal stem cells (MSCs) in the treatment of type 2 diabetes mellitus (T2DM) in order to identify a new method for treating diabetes that differs from traditional medicine and to provide a new means by which to fundamentally improve or treat diabetes. Methods: MSCs derived from adipose tissue were modified to overexpress FGF21 and GLP1, which was achieved through lentiviral particle transduction. The cells were transplanted into BKS.Cg-Dock7m+/+Leprdb/Nju mice (T2DM mouse model). Injections of physiological saline (0.1 mL) and liraglutide (0.5 mg/kg) were used as negative and positive controls, respectively. ELISA or Western blotting was used for protein analysis, and quantitative real-time PCR was used for gene expression analysis. Results: Genetic modification had no effects on the morphology, differentiation ability, or immunophenotype of MSCs. Moreover, MSC-FGF21+GLP1 cells exhibited significantly increased secretion of FGF21 and GLP1. In the T2DM mouse model, the transplantation of MSC-FGF21+GLP1 cells ameliorated the changes in blood glucose and weight, promoted the secretion of insulin, enhanced the recovery of liver structures, and improved the profiles of lipids. Moreover, FGF21 and GLP1 exerted synergistic effects in the regulation of glucolipid metabolism by controlling the expression of insulin, srebp1, and srebp2. Conclusion: Stem cell treatment based on MSCs modified to overexpress the FGF21 and GLP1 genes is an effective approach for the treatment of T2DM.Keywords
All Related Versions
Funding Information
- Postdoctoral Research Foundation of China (2019M664013)
This publication has 50 references indexed in Scilit:
- Rational Design of a Fibroblast Growth Factor 21-Based Clinical Candidate, LY2405319PLOS ONE, 2013
- Beta Cell Dysfunction and Insulin ResistanceFrontiers in Endocrinology, 2013
- Unique Responses of Stem Cell-Derived Vascular Endothelial and Mesenchymal Cells to High Levels of GlucosePLOS ONE, 2012
- Infusion of Mesenchymal Stem Cells Ameliorates Hyperglycemia in Type 2 Diabetic RatsDiabetes, 2012
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered ApproachDiabetes Care, 2012
- Transplantation of insulin-producing cells from umbilical cord mesenchymal stem cells for the treatment of streptozotocin-induced diabetic ratsJournal of Biomedical Science, 2012
- Dynamic Compression Stimulates Proteoglycan Synthesis by Mesenchymal Stem Cells in the Absence of Chondrogenic CytokinesTissue Engineering Part A, 2009
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes MellitusDiabetes, 2009
- Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese MiceDiabetes, 2009
- Immunomodulation by Mesenchymal Stem CellsDiabetes, 2008